Response to Callus et al on 'Cytoplasmic p53 is not required for PUMA-induced apoptosis' Mitochondrial outer membrane permeabilization (MOMP) is a critical event in the mitochondrial pathway of apoptosis, and this is effected and affected by the different members of the BCL-2 family of proteins.
Our paper by Chipuk et al 1 introduced the concept that complex interactions between the different types of BCL-2 proteins extends to interactions with non-BCL-2 family proteins, such as p53. Specifically, we showed that the ability of cytosolic p53 to activate the MOMP effector BAX 2 is inhibited by sequestration of cytosolic p53 by BCL-xL (as also suggested by others 3 ) and, subsequently, de-repressed by displacement of cytosolic p53 by the BH3-only protein PUMA. This scenario is an extension of the ideas of Letai and Korsmeyer, 4 ,5 upon which we have elaborated. 6 Callus et al believe that they challenge our conclusions by demonstrating that overexpression of PUMA can cause apoptosis in p53 À/À cells. However, their observation is far from novel, and represents, at best, an incremental extension of the early observations on PUMA we incorporated into our hypothesis. The original descriptions of PUMA demonstrated that its ectopic overexpression triggered apoptosis in the p53-null cell line H1299 7 and in HCT116 p53
. 8 Studies using cells from puma knockout animals showed roles for PUMA in forms of apoptosis that are known to be p53-independent. [9] [10] [11] [12] In our paper 1 (Supplementary Figure 4D and E) and in another study, 13 we showed that the PUMA BH3 domain peptide sensitized cells to apoptosis induced by BID, BIM, or staurosporine, in a p53-independent manner. The model we developed was with full knowledge of these findings, and is misrepresented by Callus et al whose observations do not contradict our results.
Callus et al also imply that our experimental use of HCT116 p53 À/À cells was not properly controlled, as we had not ruled out additional, undefined mutations in the apoptotic pathways of these cells. On the contrary, we demonstrated in Chipuk et al 1 Supplementary Figure 4D that HCT116 wild-type and p53 À/À responded similarly to staurosporine treatment indicating that apoptotic signaling upstream of mitochondria is intact. Furthermore, in Supplementary Figure 4E , HCT116 wild-type, p53 À/À , p21 À/À and p21
À/À cells responded almost identically to the BID and BIM BH3 domain peptides, arguing against any major defects in the mitochondrial pathway of apoptosis in the cells we employed.
While ectopic overexpression of PUMA can cause apoptosis in some cell lines, 7,8 a simple search for the constitutive endogenous expression of Puma in normal human tissues, pathology samples and developmental stages using the NCBI UniGene EST database 14 clearly indicates that PUMA is not, itself, sufficient to trigger apoptosis in all cases. Furthermore, there are numerous common laboratory cell lines that constitutively express PUMA protein in the absence of proapoptotic treatment (e.g., K562, HT1080, A204, NIH3T3, MOLT4, and U937); and more recently, two reports of constitutive PUMA expression in mouse embryonic fibroblasts. 15, 16 To understand this apparent paradox, it is necessary to consider the role of direct activator versus sensitizer/de-repressor BH3-only proteins in the control of BAX and/or BAK activation (Figure 1 ), as discussed in more detail elsewhere. 6 In general, cells that are transformed or otherwise stressed (e.g., by culture conditions) can become 'addicted' to the antiapoptotic members of the BCL-2 family, such that de-repression will release an activator of BAX and/or BAK to trigger MOMP and apoptosis. 5 Activators include BID, BIM, and cytosolic p53, and probably other proteins. In addition, nonprotein activators of BAX and/or BAK (e.g., heat, pH extremes) have also been described suggesting that numerous proapoptotic pathways converge on promoting an active multidomain conformation. 6, 17, 18 In contrast, PUMA acts as a de-repressor. While we cannot exclude that at some concentrations or under some conditions PUMA may directly activate BAX and/or BAK to induce MOMP, as suggested, 19 we have not found evidence for this in our work 1 (and results not shown). Recently, pharmacologic support for our model was presented in which an inhibitor of cytosolic p53 function effectively blocked DNA damage-induced cell death in vitro and in vivo, without blocking the expression of PUMA. 20 Thus, our work, along with many others, suggests that PUMA acts by releasing direct activators of BAX and BAK (e.g., BID, BIM, or p53) from antiapoptotic BCL-2 family proteins (such as BCL-xL) that sequester them. This scenario may be p53 dependent, or not, depending on the cells, conditions of sensitization, and treatment. The argument of Callus et al is specious, as it is an oversimplification and misrepresentation of our conclusions. 
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